BeOne's degrader BG-60366 appears to have been discontinued.
ApexOnco Front Page
Recent articles
The disclosure comes as another of Arcus's TIGIT trials flops.
Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.
$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.
More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.
Imfinzi scores an unexpected approval based on a post-hoc subgroup analysis.
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.